Analysts expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) to report earnings of ($0.27) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NeuBase Therapeutics’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.27). NeuBase Therapeutics posted earnings per share of ($0.20) in the same quarter last year, which indicates a negative year-over-year growth rate of 35%. The firm is scheduled to report its next earnings results on Wednesday, December 22nd.
According to Zacks, analysts expect that NeuBase Therapeutics will report full-year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.88). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.34) to ($0.87). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover NeuBase Therapeutics.
NeuBase Therapeutics (NASDAQ:NBSE) last released its earnings results on Thursday, August 12th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05).
Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of NeuBase Therapeutics during the 2nd quarter worth approximately $33,000. Heritage Wealth Advisors increased its holdings in NeuBase Therapeutics by 80.0% in the 2nd quarter. Heritage Wealth Advisors now owns 9,000 shares of the company’s stock valued at $63,000 after purchasing an additional 4,000 shares during the last quarter. Walleye Capital LLC acquired a new stake in NeuBase Therapeutics in the 2nd quarter valued at approximately $82,000. Royal Bank of Canada increased its holdings in NeuBase Therapeutics by 121.1% in the 1st quarter. Royal Bank of Canada now owns 11,244 shares of the company’s stock valued at $83,000 after purchasing an additional 6,158 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in NeuBase Therapeutics in the 2nd quarter valued at approximately $92,000. Institutional investors and hedge funds own 31.85% of the company’s stock.
NBSE opened at $3.89 on Monday. The company’s 50 day simple moving average is $3.72 and its two-hundred day simple moving average is $4.67. NeuBase Therapeutics has a 1-year low of $3.26 and a 1-year high of $12.89. The firm has a market capitalization of $127.27 million, a price-to-earnings ratio of -4.27 and a beta of -0.01.
NeuBase Therapeutics Company Profile
NeuBase Therapeutics, Inc is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy.
Recommended Story: Most Volatile Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.